EquityBulls

Latest News

Keywords Selected: INE089A01023

Research

Dr. Reddy's Laboratories - Analyst Meet Update - Multiple growth initiatives - BUY

Stock Report

Aurigene Oncology Ltd announces promising results of Phase 1 study for India's first trial for novel autologous CAR-T cell therapy for multiple myeloma
Dr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countries
Dr. Reddy's Laboratories Ltd receives order from COFEPRIS
Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar
Dr. Reddy's signs non-exclusive patent licensing agreement with Takeda to commercialise Vonoprazan
Zydus and Dr. Reddy's announce licensing agreement for co‐marketing of Pertuzumab biosimilar
Dr. Reddy's to acquire Nicotinell and related portfolio
LIC increases stake in Dr. Reddys Laboratories Ltd
Dr. Reddy's Laboratories Limited gets Form 483 from USFDA with 4 observations for API facility
Aurigene Pharmaceutical Services Ltd opens biologics facility in Genome Valley, Hyderabad
Dr. Reddy's Laboratories Limited recommends final dividend of Rs. 40
Dr. Reddy's Laboratories announces the launch of Doxycycline Capsules, 40 mg* in the U.S.
Nestlé India and Dr. Reddy's to form joint venture to take health science nutraceutical portfolio to consumers across India and other agreed territories
Dr. Reddy's launches Condition Management programme 'DailyBloom™ IBS'
Dr. Reddy's launches drug-free migraine management device Nerivio® in Europe following successful launch in India
Bayer and Dr. Reddy's sign a marketing and distribution agreement for second brand of Vericiguat™ in India
Dr. Reddy's enters into exclusive distribution partnership with Sanofi Healthcare India Pvt Ltd for their vaccine brands in India
Dr. Reddy's and Pharmazz, Inc. enter into licensing agreement to market first-in-class Centhaquine for hypovolemic shock in India
Dr. Reddy's Laboratories launches Versavo® in the UK
Dr. Reddy's announces the acquisition of MenoLabs®, a leading women's health and dietary supplements portfolio of brands
Dr. Reddy's Laboratories, Inc. acquires Preferred A-1 shares of Edity Therapeutics Ltd
Dr. Reddy's becomes first Indian pharma company to debut on the Dow Jones Sustainability World Index
Dr. Reddy's Laboratories Ltd gets 3 observations from USFDA for R&D Centre
Dr. Reddy's Laboratories SA enters into agreement for COYA 302